{"id":"W3134020977","doi":"10.1172/jci.insight.95042","title":"Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Center for Advancing Translational Sciences; Medical Research Council; University of Oxford; Genentech; Innovative Medicines Initiative; Fondation Leducq; Wellcome Trust; Cancer Research UK; Novartis Pharma; Francis Crick Institute; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; International Fibrodysplasia Ossificans Progressiva Association; National Institutes of Health; Ontario Genomics; Fundação de Amparo à Pesquisa do Estado de São Paulo; U.S. Department of Defense; Diamond Light Source; Genome Canada; National Heart, Lung, and Blood Institute; Pfizer; Harvard Stem Cell Institute; McGill University","keywords":"Fibrodysplasia ossificans progressiva; Heterotopic ossification; Medicine; Myositis ossificans; Bone morphogenetic protein; Soft tissue; Bioinformatics; Internal medicine; Cancer research; Pathology; Anatomy; Genetics; Biology; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002540961,0.0002363005,0.0003956283,0.0003368921,0.0001862558,0.0004054609,0.0002086365,0.0003569671,0.002889606],"category_scores_gemma":[0.0001694544,0.0000804111,0.0002603242,0.0001903948,0.0002128358,0.0002840761,0.0001598128,0.0009353439,0.0006692634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002423225,"about_ca_system_score_gemma":0.0002896907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002193214,"about_ca_topic_score_gemma":0.0008045998,"domain_scores_codex":[0.9999208,0.00001448805,0.000008139673,0.00001407542,0.00002371589,0.0000187489],"domain_scores_gemma":[0.9999411,0.000009560388,0.00001718304,0.000005465475,0.000008891974,0.00001773802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006171999,0.001832531,0.004188409,0.00126477,0.000187603,0.00240549,0.0001431852,0.001693545,0.6945663,0.004290964,0.009613053,0.2736422],"study_design_scores_gemma":[0.00946431,0.04261288,0.03195605,0.0003255407,0.0007462279,0.01889731,0.0003205765,0.007093364,0.5987374,0.002215369,0.2875055,0.0001255198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9211318,0.04421254,0.004166429,0.003077257,0.000433118,0.0005576105,0.001784922,0.0006186855,0.0240176],"genre_scores_gemma":[0.9806395,0.008645196,0.001961963,0.0006371154,0.00008154679,0.000166799,0.001750289,0.00002009827,0.006097505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002889606,"threshold_uncertainty_score":0.009666681,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08590255119467977,"score_gpt":0.4106181409906178,"score_spread":0.324715589795938,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}